Journal of Clinical Pharmacy and Therapeutics最新文献

{"title":"Antidepressant Adverse Reactions in Adult and Older Adult Populations: A Comparative Study From the Portuguese Pharmacovigilance System (2010–2020)","authors":"Ana Catarina Coelho,&nbsp;Cristina Monteiro,&nbsp;Maria Vaz Patto","doi":"10.1155/jcpt/2448331","DOIUrl":"https://doi.org/10.1155/jcpt/2448331","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The use of antidepressants in Portugal has been increasing, raising concerns about their potential to cause adverse drug reactions (ADRs), particularly in vulnerable populations. This study aimed to characterize all ADRs associated with antidepressant use reported between January 1, 2010, and December 31, 2020, and to compare these findings between adults and older adults.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective descriptive study was conducted using data from the Portuguese Pharmacovigilance System (PPS) database. The analysis considered age, sex, pharmacological group, ADR seriousness, and type of reporter.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 751 ADRs cases were identified (496 in adults; 255 in older adults). Women accounted for the majority of ADRs in both groups, with 70.97% (<i>n</i> = 352) of cases in adults and 67.84% (<i>n</i> = 173) in older adults. Selective serotonin reuptake inhibitors (SSRIs) were the primary contributors to ADRs in adults (33.43%), while tricyclic antidepressants (TCAs) were the leading cause in older adults (46.86%). Serious ADRs were predominant in both groups. In adults, marketing authorization holders (MAHs) were the primary reporters, whereas physicians and pharmacists played a more active role in reporting ADRs in older adults.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings highlight the need for continuous monitoring and reporting of antidepressant-related ADRs, given their significant association with serious adverse outcomes. The predominance of TCAs in ADR reports and the high proportion of serious cases underscore the need for careful prescribing of these drugs. However, the absence of denominator data limits the assessment of the true incidence and relative risk of ADRs associated with antidepressants. Even though these results support the role of real-world data in improving medication safety and informing clinical and regulatory decision-making.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/2448331","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148848983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Potentially Inappropriate Medication Use in Patients Aged ≥ 80 Years With Atrial Fibrillation According to STOPP Criteria Version 3 and 2023 Beers Criteria","authors":"Ying Bai,&nbsp;Jianqi Wang,&nbsp;Guangyao Li,&nbsp;Zhen Zhou","doi":"10.1155/jcpt/7149111","DOIUrl":"https://doi.org/10.1155/jcpt/7149111","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; What is Known and Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The presence of potentially inappropriate medications (PIMs) is associated with drug-related harmful effects, including adverse drug events, elevated rates of hospital readmissions, and higher mortality rates. Patients aged ≥ 80 years with atrial fibrillation (AF) often present with multiple comorbidities and polypharmacy; however, evidence regarding PIM usage in this specific population is still limited. Consequently, this study investigated the prevalence of PIMs in patients with AF aged ≥ 80 years and identified the factors associated with PIM use.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This retrospective cross-sectional study was conducted at Beijing Tongren Hospital and included patients aged ≥ 80 years with AF who were discharged from the internal medicine wards between July 2021 and July 2024. PIMs in discharge medications were identified using the STOPP criteria Version 3 and 2023 Beers criteria. Patients who received at least one PIM were categorized into the PIM group. Consistency between the two screening tools was evaluated using the kappa test. Variables collected included gender, age, estimated glomerular filtration rate (eGFR), length of stay, age-adjusted Charlson Comorbidity Index (aCCI), Barthel index, comorbidities, and the number of medications. Multivariable binary logistic regression was used to identify factors correlated with the incidence of PIMs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results and Discussion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Among 425 patients aged ≥ 80 years with AF, the prevalence rates of at least one PIM were 35.5% and 73.4% according to the STOPP criteria version 3 and 2023 Beers criteria, respectively. Among patients who received PIMs, the majority received only one PIM, accounting for 27.8% and 40.9% according to the STOPP criteria Version 3 and 2023 Beers criteria, respectively. Benzodiazepines, antiplatelets, and z-drugs were the top three PIMs according to STOPP criteria version 3, whereas diuretics, rivaroxaban, and benzodiazepines were the top three PIMs according to 2023 Beers criteria. A poor concordance was observed between the two criteria (&lt;i&gt;k&lt;/i&gt; = 0.117, 95% confidence interval: 0.050–0.184; &lt;i&gt;p&lt;/i&gt; = 0.01). The number of medications was associated with the prevalence of PIMs for both criteria (&lt;i&gt;p&lt;/i&gt; &lt; 0.001).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; What is New and Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The prevalence of PIMs among patients aged ≥ 80 years with AF was relatively high. The STOPP criteria Version 3 identified a lower prevalence of PIMs than the 2023 Beers criteria, and the agree","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/7149111","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148848814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardamonin Impairs Glutamine-Dependent Growth in Ovarian Cancer Cells Through Suppression of mTORC1/Glutaminase","authors":"Danyun Li,&nbsp;Peiguang Niu,&nbsp;Yanting Zhu,&nbsp;Huajiao Chen,&nbsp;Qiuhua Ding","doi":"10.1155/jcpt/5621631","DOIUrl":"https://doi.org/10.1155/jcpt/5621631","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Metabolic reprogramming contributes to ovarian cancer progression and therapeutic resistance, and glutamine utilization plays a critical role in supporting tumor growth and maintaining redox homeostasis. Cardamonin, a naturally occurring chalcone compound, has demonstrated antitumor activity in several malignancies; however, its effects on glutamine metabolism in ovarian cancer remain unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Human ovarian cancer SKOV3 and A2780 cells were cultured under glutamine-sufficient and glutamine-deprived conditions and treated with cardamonin to evaluate its antiproliferative effects. Cell viability was assessed by CCK-8 assay. Apoptosis and intracellular reactive oxygen species (ROS) levels were measured by flow cytometry. The expression of glutaminase and mTORC1 pathway-related proteins was examined by western blotting. In addition, Raptor-deficient SKOV3 cells were used to further investigate the underlying mechanism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Cardamonin significantly inhibited ovarian cancer cell proliferation, with more pronounced suppressive effects observed under glutamine-rich conditions. In addition, cardamonin increased apoptotic cell populations and promoted ROS accumulation in SKOV3 cells. Western blot analysis demonstrated that cardamonin decreased glutaminase expression and reduced phosphorylation of S6K1. Similar suppression of glutaminase expression was observed following rapamycin treatment. Furthermore, Raptor deficiency reduced glutaminase expression and attenuated the inhibitory effects of cardamonin on glutaminase expression and S6K1 phosphorylation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings suggest that cardamonin impairs glutamine-dependent ovarian cancer cell growth through inhibiting glutaminase expression, which is associated with blockade of the mTORC1 signaling pathway. Collectively, the present study supports glutamine metabolism as a potential therapeutic target of cardamonin in ovarian cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5621631","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148752956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Cardiac Adverse Event Signals for Natural Products Using Disproportionality Analysis of the FDA Adverse Event Reporting System (FAERS)","authors":"Christina L. Kazarov,&nbsp;Richard D. Boyce,&nbsp;Sanya B. Taneja,&nbsp;Kojo Abanyie,&nbsp;Maryann R. Sestito,&nbsp;Sandra L. Kane-Gill","doi":"10.1155/jcpt/8979418","DOIUrl":"https://doi.org/10.1155/jcpt/8979418","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Marketing regulations for natural products (NPs), such as herbal supplements, are less stringent than for prescription or over-the-counter medications. This paucity of regulations and widespread use demonstrates the need to better understand potential safety risks of NPs. The aim of this disproportionality analysis was to use the FDA Adverse Event Reporting System (FAERS) database to identify cardiac adverse event (AE) signals associated with NPs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>FAERS reports (2004 Q1–2021 Q3) were searched for cardiac AEs and NP use. Reporting odds ratios (ROR) were calculated for each cardiac AE–NP pair. Pairs with ≥ 3 reports and a 95% confidence interval for the ROR ≥ 2.0 underwent further analysis using the observed-to-expected (OE) ratio with shrinkage. Signals with an OE ratio 95% credibility interval &gt; 1.0 were considered significant safety signals. Detailed assessments of each report were conducted for content validity based on clinical interpretation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 2484 spontaneous reports listing cardiac AEs and NPs were identified, resulting in 705 preliminary NP–AE pairs for 74 unique NPs. Subsequent OE ratio calculations identified 10 significant safety signals for 8 unique NPs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Several AE signals for NPs had a disproportionate number of reports when compared to all other product reports within FAERS. After a literature search for supporting evidence, we found that four NPs are likely associated with cardiac AEs (guarana, hemp extract, licorice, and ginkgo) and four require further investigation (seawrack, soybean, celery, and <i>Panax ginseng</i>). Despite limitations inherent to spontaneous reporting systems, this study highlights potential cardiac safety risks associated with NP use.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/8979418","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148752378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESSION OF CONCERN: Hydroxychloroquine: Pharmacokinetics and Toxicity","authors":"","doi":"10.1155/jcpt/9791837","DOIUrl":"https://doi.org/10.1155/jcpt/9791837","url":null,"abstract":"<p>EXPRESSION OF CONCERN: P. Brouqui, E. Chabriere, and D. Raoult, “Hydroxychloroquine: Pharmacokinetics and Toxicity,” <i>Journal of Clinical Pharmacy and Therapeutics</i>, 2024, 6500340, 12 pages, 2024. https://doi.org/10.1155/2024/6500340.</p><p>This Expression of Concern is for the above article, published online on 24 January 2024 in Wiley Online Library (https://wileyonlinelibrary.com), and has been issued by John Wiley &amp; Sons Ltd. The Expression of Concern has been agreed due to questions raised about the study’s adherence to French legal and ethical requirements for research involving human subjects. Additionally, concerns have been raised for ten of the referenced articles. The investigation into these concerns is ongoing. Therefore, the journal has decided to issue an Expression of Concern to inform and alert readers.</p>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/9791837","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Clinical Pharmacist Interventions With Outcomes in Severe Diabetic Foot Infections: A Retrospective Cohort Study","authors":"Ping Wu,&nbsp;Chunyan Ni,&nbsp;Xuemei Sun,&nbsp;Wendong Xu","doi":"10.1155/jcpt/5279339","DOIUrl":"https://doi.org/10.1155/jcpt/5279339","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;It is common for clinical pharmacists to participate in the management of antimicrobial therapy in many countries, but not all countries have clinical pharmacists participating in the antimicrobial treatment of patients with diabetic foot.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aim&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To evaluate the effects of the involvement of clinical pharmacists in the management of severe infection in patients with diabetic foot.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 89 patients with severe diabetic foot infection were enrolled in this retrospective study from January 2020 to December 2024, and they were divided into the study group (SG, &lt;i&gt;n&lt;/i&gt; = 44) and the control group (CG, &lt;i&gt;n&lt;/i&gt; = 45). Patients in the SG received clinical pharmacist intervention during hospitalization, while those in the CG received only general services. The Student′s &lt;i&gt;t&lt;/i&gt;-test and the Mann–Whitney &lt;i&gt;U&lt;/i&gt; test were used for intergroup comparison of continuous variables, while the Chi-square test was adopted for categorical variables.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;No significant differences were identified between the SG and CG with respect to their sociodemographic or infection characteristics. The median duration of fever was shorter in the SG (3.00 days) than in the CG (6.00 days). After 3 days of antimicrobial treatment, the SG showed significantly larger decreases in the WBC count, C-reactive protein (CRP), and procalcitonin (PCT) than the CG (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). The SG had a significantly higher prevalence of appropriate initial empirical antimicrobial therapy (93.18% vs. 48.89%, &lt;i&gt;p&lt;/i&gt; = 0.001), fewer drug-related complications (13.64% vs. 51.11%, &lt;i&gt;p&lt;/i&gt; &lt; 0.001), and a lower prevalence of readmission over the first 12 months following discharge (2.27% vs. 17.78%, &lt;i&gt;p&lt;/i&gt; = 0.030). The prevalence of antimicrobial regimen adjustments of ≥ 2 was also lower in the SG group (9.10% vs. 35.56%, &lt;i&gt;p&lt;/i&gt; = 0.004). There were no significant differences in the prevalence of amputation or the defined daily dose between the groups.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The involvement of clinical pharmacists in the management of severe infection in patients with diabetic foot was associated with improved acute infection control and the alleviation of drug-related problems associated with antimicrobial agents, thereby providing a valuable reference for antimicrobial therapy management in such patients.&lt;/p&gt;\u0000","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5279339","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Glomerular Filtration Rate on Potentially Inappropriate Medications in Older Adults: A Cross-Sectional Study","authors":"Qingmin Yao,&nbsp;Yanxia Liu,&nbsp;Ting Yuan,&nbsp;Wen Zhang,&nbsp;Yahui Zhang,&nbsp;Wen Chen,&nbsp;Xiaojuan Zhu,&nbsp;Jianchun Wang","doi":"10.1155/jcpt/6682398","DOIUrl":"https://doi.org/10.1155/jcpt/6682398","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to assess the association between estimated glomerular filtration rate (eGFR) levels and the prevalence of potentially inappropriate medications (PIMs) based on three criteria: the Beers (2019 version), Chinese, and Screening Tool of Older Persons’ Prescriptions (STOPP) criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cross-sectional study analyzed 191 inpatients aged ≥ 65 years. Using the Beers, Chinese, and STOPP criteria, we assessed the prevalence of PIMs across stratified eGFR levels. Nonparametric analyses (Mann–Whitney <i>U</i> test), chi-square tests, and logistic regression analysis were employed to evaluate the association between eGFR and PIMs exposure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Participants were stratified into three groups based on eGFR: Group I (≥ 90 mL/min/1.73 m²), Group II (60–89 mL/min/1.73 m²), and Group III (&lt; 60 mL/min/1.73 m²). Prevalence rates of PIMs were 72.25% by Beers criteria, 60.73% by Chinese criteria, and 28.80% by STOPP criteria, with STOPP demonstrating significantly lower PIMs detection rates than the other two criteria. Analysis by eGFR stratification revealed escalating PIMs prevalence with declining kidney function under Beers criteria: 67.35% in Group I, 74.29% in Group II, and 86.96% in Group III (<i>p</i> &lt; 0.05). Notably, Group III (eGFR &lt; 60 mL/min/1.73 m²) exhibited higher proportions of patients with ≥ 2 PIMs across all criteria. By Beers criteria, 56.52% of Group III patients had ≥ 2 PIMs versus 22.45% (Group I) and 25.71% (Group II). Similar trends were observed by Chinese and STOPP criteria (<i>p</i> &lt; 0.05). Logistic regression analysis identified polypharmacy and eGFR decline as independent risk factors for PIMs exposure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The prevalence of PIMs gradually increases with the decline of eGFR in older adults, particularly when compounded by polypharmacy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/6682398","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients","authors":"Jing Kai Lam,&nbsp;Xiaoyan Yang,&nbsp;Baharudin Ibrahim,&nbsp;Amirrudin Kamsin,&nbsp;Jinxin Zhao,&nbsp;S. Y. Amy Cheung,&nbsp;Xiaofen Liu,&nbsp;Jamaludin Elis,&nbsp;Nusaibah Abdul Rahim,&nbsp;Yu-Wei Lin","doi":"10.1155/jcpt/7870942","DOIUrl":"https://doi.org/10.1155/jcpt/7870942","url":null,"abstract":"<p>Precision medicine has transformed healthcare by moving toward individualized treatment strategies, yet dosing optimization for pediatric patients remains a complex challenge. Therapeutic drug monitoring (TDM), a widely used practice in clinical settings, provides a foundation for achieving therapeutic goals but poses significant limitations, particularly in the pediatric population, due to the frequent need for blood sampling and delayed adjustments. Model-informed precision dosing (MIPD) is an emerging strategy that combines population pharmacokinetic (pop-PK) models with patient-specific data to enhance therapeutic outcomes while minimizing the need for invasive procedures. This narrative review highlights the potential of MIPD in pediatric antimicrobial therapy, with an emphasis on its applications, advantages, and current challenges. By analyzing recent advancements in pop-PK models for antimicrobials, this review article underscores MIPD’s ability to optimize dosing strategies and improve clinical outcomes for pediatric patients. Despite the barriers to widespread implementation, such as data availability and regulatory hurdles, MIPD offers a path forward for precision medicine in pediatrics. By bridging the gap between computational modeling and clinical practice, MIPD has the potential to reshape the future of pediatric pharmacotherapy.</p>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/7870942","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in Clinical Pharmacy: From Decision Support to Prescription Execution","authors":"Wenshuo Jiang,&nbsp;Yuntian Wang,&nbsp;Weizhong Shi,&nbsp;Cao Li,&nbsp;Mingda Li,&nbsp;Yongqiang Tang,&nbsp;Xiaolin Yue,&nbsp;Zhigang Zhao","doi":"10.1155/jcpt/4675298","DOIUrl":"https://doi.org/10.1155/jcpt/4675298","url":null,"abstract":"<p>Artificial intelligence (AI) is emerging and showing great potential in optimizing clinical pharmacy. This review aims to provide an overview of applications and advances of AI in clinical pharmacy. The findings illustrated that AI can assist in various stages from decision support to prescription execution supporting safer and more effective therapeutic practice. Machine learning and natural language processing are useful tools for tasks such as drug therapy recommendation, precision dosing, adverse drug event prediction and improving medication adherence. This study summarizes the latest progress in AI technologies within clinical medication from the view of both pharmacists and AI specialists. Future efforts should focus on addressing challenges like data quality issues to steadily advance AI-driven clinical medication development.</p>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/4675298","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Characteristics of Deoxycholate and Liposomal Amphotericin B Adverse Reactions in a Third-Level Care Hospital: A Retrospective Observational Study","authors":"Thalia Berenice Jacobo Vargas,&nbsp;Miriam del Carmen Carrasco Portugal,&nbsp;Renata Báez Saldaña,&nbsp;Odalis Rodríguez Ganen,&nbsp;Francisco Javier Flores Murrieta,&nbsp;Victor Hugo Ahumada Topete,&nbsp;Ricardo Stanley Vega Barrientos","doi":"10.1155/jcpt/2980716","DOIUrl":"https://doi.org/10.1155/jcpt/2980716","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>We aimed to establish the prevalence of adverse reactions associated with the use of deoxycholate and/or liposomal amphotericin B and to determine adherence to World Health Organization (WHO) recommendations to minimize the risk of toxicity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Clinical data were collected from records of 143 patients over 18 years of age who were under treatment with amphotericin B (deoxycholate and/or liposomal) for at least 5 days from January 2016 to March 2019 at National Institute of Respiratory Diseases “Ismael Cosío Villegas” in Mexico City. We used MeSH terms to name each formulation of amphotericin B, adverse reactions, and diagnoses. Definitions and classification of the adverse reactions were made in accordance with the Common Terminology Criteria for Adverse Events Version 5.0 and other bibliographic references. Preventability assessment was evaluated using the Schumock and Thornton scale. To determine adherence to WHO recommendations, we evaluated intravenous preemptive hydration, electrolyte supplementation, and laboratory test monitoring.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>105 patients (73.4%) were exposed to deoxycholate amphotericin B, 25 patients (17.5%) to liposomal amphotericin B, and 13 patients (9.1%) to both amphotericin B types. Hypokalemia was the most common adverse reaction (76.2%), followed by hypomagnesemia (47.6%), acute kidney injury (40.6%), infusion reactions (33.6%), anemia (20.3%), thrombocytopenia (7%), and neutropenia (4.9%). Electrolyte supplementation was the WHO recommendation that was less performed (28%), while preemptive hydration and laboratory test monitoring were well applied (82.5% and 84.6%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study highlights the need to adhere to amphotericin B toxicity prevention recommendations as some of the most common adverse reactions are mostly preventable.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/2980716","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148324032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}